Peroxisome proliferator-activated receptors and thiazolidinediones in diabetic nephropathy
Abstract
Keywords
Full Text:
PDFReferences
Furukawa M, Gohda T, Tanimoto M, Tomino Y. Pathogenesis and novel treatment from the mouse model of type 2 diabetic nephropathy. Scientific World J. 2013;2013:1-8.
Soni NO. Embryonic life of HDACs inhibitor-in diabetic nephropathy. World J Pharm Pharmaceutical Sci. 2017;6:345-59.
Soni NO. NADPH oxidase is novel drug in diabetic nephropathy. World J Pharm Pharmaceutical Sci. 2017;6:765-75.
Soni NO. TGF-β is novel drugs in diabetic nephropathy. World J Pharm Pharmaceutical Sci. 2017;6:622-45.
Soni NO. Drugs for diabetic nephropathy-full review. World J Pharm Pharmaceutical Sci. 2017;6:1958-2022.
Davis L, Guan Y, Zhang Y, Breyer RM, Breyer MD. Activity is associated with renal microvasculature. Am J Physiol Renal Physiol. 2001;281(6):1036-46.
Lee EY, Kim GT, Hyun M, Kim S, Seok S, Choi R, et al. Peroxisome proliferator-activated receptor-δ activation ameliorates albuminuria by preventing nephrin loss and restoring podocyte integrity in type 2 diabetes. Nephrol Dial Transplant. 2012;27:4069-79.
Sarafidis PA, Georgianos PI, Lasaridis AN. PPAR-γ Agonism for cardiovascular and renal protection. Cardiovascular Therapeutic. 2011;29:377-84.
Nakamura T, Ushiyama C, Osada S, Hara M, Shimada N, Koide H. Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria. Metab Clin Exp. 2001;50:1193-96.
Yamashita H, Nagai Y, Takamura T, Nohara E, Kobayashi K. Thiazolidinedione derivatives ameliorate albuminuria in streptozotocin-induced diabetic spontaneous hypertensive rat. Metab Clin Exp. 2002;51:403-8.
Yotsumoto T, Naitoh T, Kanaki T, Matsuda M, Tsuruzoe N. A novel peroxisome proliferator-activated receptor (PPAR) gamma agonist, NIP-222, reduces urinary albumin excretion in streptozotocin-diabetic mice independent of PPAR gamma activation. Metab Clin Exp. 2003;52:1633-7.
Tanimoto M, Fan Q, Gohda T, Shike T, Makita Y, Tomino Y. Effect of pioglitazone on the early stage of type 2 diabetic nephropathy in KK/Ta mice. Metab Clin Exp. 2004;53:1473-9.
Zafiriou S, Stanners SR, Saad S, Polhill TS, Poronnik P, Pollock CA. Pioglitazone inhibits cell growth and reduces matrix production in human kidney fibroblasts. J Am Soc Nephrol. 2005;16:638-45.
Kubota N, Terauchi Y, Kubota T, Kumagai H, Itoh S, Satoh H, et al. Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and-independent pathways. J Biol Chem. 2006;281:8748-55.
Yang HC, Ma LJ, Ma J, Fogo AB. Peroxisome proliferator-activated receptor-gamma agonist is protective in podocyte injury-associated sclerosis. Kidney Int. 2006;69:1756-64.
Okada T, Wada J, Hida K, Eguchi J, Hashimoto I, Baba M, et al. Thiazolidinediones ameliorate diabetic nephropathy via cell cycle-dependent mechanisms. Diabetes. 2006;55:1666-77.
Katavetin P, Eiam-Ong S, Suwanwalaikorn S. Pioglitazone reduces urinary protein and urinary transforming growth factor-beta excretion in patients with type 2 diabetes and overt nephropathy. J Med Assoc Thai. 2006;89:170-7.
Cha DR, Zhang X, Zhang Y, Wu J, Su D, Han JY, et al. Peroxisome Proliferator-activated receptor α/γ dual agonist tesaglitazar attenuates diabetic nephropathy in db/db mice. Diabetes. 2007;56:2036-45.
Yu X, Li C, Li X, Cai L. Rosiglitazone prevents advanced glycation end products-induced renal toxicity likely through suppression of plasminogen activator inhibitor-1. Toxicol Sci. 2007;96:346-56.
Ko GJ, Kang YS, Han SY, Lee MH, Song HK, Han KH, et al. Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. Nephrol Dial Transplant. 2008;23:2750-60.
Orasanu G, Ziouzenkova O, Devchand PR, Nehra V, Hamdy O, Horton ES, et al. The peroxisome proliferator-activated receptor-gamma agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor- alpha- dependent manner in vitro and in vivo in mice. J Am Coll Cardiol. 2008;52:869-81.
Kawai T, Masaki T, Doi S, Arakawa T, Yokoyama Y, Doi T, et al. PPAR-gamma agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-beta. Lab Invest. 2009;89:47-58.
Flaquer M, Lloberas N, Franquesa M, Torras J, Vidal A, Rosa JL, et al. The combination of sirolimus and rosiglitazone produces a renoprotective effect on diabetic kidney disease in rats. Life Sci. 2010;87:147-53.
Setti G, Hayward A, Dessapt C, Barone F, Buckingham R, White K, et al. Peroxisome proliferator-activated receptor-γ agonist rosiglitazone prevents albuminuria but not glomerulosclerosis in experimental diabetes. Am J Nephrol. 2010;32:393-402.
Atanasov AG, Wang JN, Gu SP, Bu J, Kramer MP, Baumgartner L, et al. Honokiol: a non-adipogenic PPARγ agonist from nature. Biochim Biophys Acta. 2013;1830:4813-9.
Huang KC, Cherng YG, Chen LJ, Hsu CT, Cheng JT. Rosiglitazone is effective to improve renal damage in type-1-like diabetic rats. Horm Metab Res. 2014;46:240-4.
Jesse CR, Bortolatto CF, Wilhelm EA, Roman SS, Prigol M, Nogueira CW. The peroxisome proliferator-activated receptor-γ agonist pioglitazone protects against cisplatin-induced renal damage in mice. J Appl Toxicol. 2014;34:25-32.
Jia Z, Sun Y, Yang G, Zhang A, Huang S, Heiney KM, et al. New Insights into the PPAR γ Agonists for the Treatment of Diabetic Nephropathy. PPAR Res. 2014;2014:1-7.
Platt C, Coward RJ. Peroxisome proliferator activating receptor-γ and the podocyte. Nephrol Dial Transplant. 2017;32:423-33.
Cooper M, Warren AM. A promising outlook for diabetic kidney disease. Nature Reviews Nephrol. 2019;15:68-70.
Ohga S, Shikata K, Yozai K, Okada S, Ogawa D, Usui H, et al. Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-kappaB activation. Am J Physiol Renal Physiol. 2007;292:1141-50.
Wang W, Liu F, Chen N. Peroxisome proliferator-activated receptor- γ (PPAR- γ ) agonists attenuate the profibrotic response induced by TGF- β 1 in renal interstitial fibroblasts. Mediators Inflamm. 2007;2007:1-7.
Corrales P, Izquierdo-Lahuerta A, Medina-Gomez G. Maintenance of kidney metabolic homeostasis by PPAR gamma. Int J Mol Sci. 2018;19(7):e2063.
Lee EY, Kim GT, Hyun M, Kim S, Seok S, Choi R, et al. Peroxisome proliferator-activated receptor-δ activation ameliorates albuminuria by preventing nephrin loss and restoring podocyte integrity in type 2 diabetes. Nephrol Dialysis Transplant. 2012;27:4069-79.
Sugawara A, Uruno A, Matsuda K, Saito-Ito T, Funato T, Saito-Hakoda A, et al. Effects of PPARγ agonists against vascular and renal dysfunction. Curr Mol Pharmacol. 2012;5:248-54.
Yang J, Zhou Y, Guan Y. PPARγ as a therapeutic target in diabetic nephropathy and other renal diseases. Curr Opin Nephrol Hypertens. 2012;21:97-105.
Guan Y, Breyer MD. Peroxisome proliferator-activated receptors (PPARs): Novel therapeutic targets in renal disease. Kidney Int. 2001;60:14-30.
Panchapakesan U, Chen XM, Pollock CA. Drug insight: thiazolidinediones and diabetic nephropathy-relevance to renoprotection. Nat Clin Pract Nephrol. 2005;1:33-43.
Chung BH, Lim SW, Ahn KO, Sugawara A, Ito S, Choi BS, et al. Protective effect of peroxisome proliferator activated receptor gamma agonists on diabetic and non-diabetic renal diseases. Nephrol (Carlton). 2005;10:S40-3.
Yang J, Zhang D, Li J, Zhang X, Fan F, Guan Y. Role of PPAR gamma in renoprotection in type 2 diabetes: molecular mechanisms and therapeutic potential. Clin Sci. 2009;116:17-26.